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Depression risk is exacerbated by genetic factors
and stress exposure; however, the biological mech-
anisms through which these factors interact to
confer depression risk are poorly understood. One
putative biological mechanism implicates variability
in the ability of cortisol, released in response to
stress, to trigger a cascade of adaptive genomic
and non-genomic processes through glucocorticoid
receptor (GR) activation. Here, we demonstrate that
common genetic variants in long-range enhancer
elements modulate the immediate transcriptional
response to GR activation in human blood cells.
These functional genetic variants increase risk for
depression and co-heritable psychiatric disorders.
Moreover, these risk variants are associated with
inappropriate amygdala reactivity, a transdiagnostic
psychiatric endophenotype and an important stress
hormone response trigger. Network modeling and
animal experiments suggest that these genetic dif-
ferences in GR-induced transcriptional activation
may mediate the risk for depression and other psy-
chiatric disorders by altering a network of function-
ally related stress-sensitive genes in blood and
brain.INTRODUCTION
Major depressive disorder (MDD) has a lifetime prevalence of
up to 17% (Kessler et al., 2005), resulting in one of the highest
global burden of disease ratings by the World Health Organiza-
tion (Ustu¨n et al., 2004). Despite its prevalence and impact,
the etiological and pathophysiological mechanisms underlying
MDD are poorly understood, resulting in sub-optimal treat-
ments with high rates of recurrence and treatment resistance
(Warden et al., 2007). Family, twin, and population studies point
to both genetic as well as environmental risk factors for depres-
sion. Genetic factors contribute up to 40% of the risk and
are complemented largely by individual-specific environmental
exposure to adverse life events (Kendler et al., 2006). Both
sensitivity and resilience to the long-term effects of exposure
to adverse life events may be modulated by genetic variation
(Kendler, 2013).
Stress results in activation of the stress hormone system,
which culminates in the activation of glucocorticoid receptors
(GRs) by cortisol. The GR is a nuclear hormone receptor, and
upon activation it translocates from the cytoplasm to the nu-
cleus, where it binds to glucocorticoid response elements
(GREs) and regulates gene expression (McKay and Cidlowski,
1999; Phuc Le et al., 2005). Activation of this receptor not
only initiates adaptive physiological changes in the body to
confront an imminent threat, but also facilitates the termination
of these changes once the threat has been overcome. Thus,
genetically driven variability in GR regulation of the stressNeuron 86, 1189–1202, June 3, 2015 ª2015 The Authors 1189
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Figure 1. Summary Figure Illustrating the
Sequence of Experiments and Analyses
Applied in This Study
The main hypothesis tested in this study is that
common genetic variants that alter the short-term
transcriptional response to GR activation also alter
the risk for stress-related psychiatric disorders and
related neural endophenotypes.hormone response may functionally interact with environmental
risk factors, thereby producing individual differences in risk
for MDD.1190 Neuron 86, 1189–1202, June 3, 2015 ª2015 The AuthorsConsistent with this model, dysfunction
of GR-mediated negative feedback has
been reported in MDD (de Kloet et al.,
2005) as well as in individuals exposed
to early adversity (Heim and Binder,
2012; Wilkinson and Goodyer, 2011),
one of the strongest risk factors for the
development of MDD. Moreover, genetic
variation in pathways regulating GR
signaling has been linked with MDD risk
(van Rossum et al., 2006). Here, we
show that common genetic variants that
modulate the initial transcriptional
response to GR activation increase the
risk for MDD as well as other psychiatric
disorders. Gene network modeling and
animal experiments suggest that these
genetic differences in the transcriptional
response to GR activation may mediate
risk for depression and other psychiatric
disorders by altering a network of co-ex-
pressed genes that are responsive to
stress and glucocorticoids in the brain.
In addition, these genetic variants shape
the response of the amygdala, which is it-
self an important trigger of the stress hor-
mone response and a functional neural
phenotype implicated in the etiology and
pathophysiology of depression and other
forms of psychopathology (Jankord and
Herman, 2008; Phillips et al., 2003). The
main hypotheses and the experimental
approach are summarized in Figure 1.
RESULTS
Genetic Regulation of GR-
Stimulated Gene Expression
We first identified genetic variants that
alter GR-stimulated gene expression
changes by adopting a stimulated ex-
pression quantitative trait locus (eQTL)
approach (Figure 2A). Gene expression
profiles in peripheral blood cells from 160
male individuals of the Max-Planck Insti-tute of Psychiatry (MPIP) cohort (91 cases and 69 controls, see
Experimental Procedures) were obtained at baseline and 3 hr
after stimulation with the selective GR agonist dexamethasone
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Figure 2. GR-Response-Modulating cis-eQTLs
(A) Study design for GR-stimulated gene expression in whole blood of 160 male individuals from the Max Planck Institute of Psychiatry cohort.
(B) Circularized Manhattan plot displaying cis-associations for GR-response eQTL bins (n = 320) and their respective significance (log10 Q values). Displayed
from the outer to the inner circle are the number of chromosomes, the ideograms for the human karyotype (hg18), genes nearby eSNPs, and Manhattan plots for
the eQTL bins that survived correction for multiple testing.
(C and D) Boxplots of human gene expression values for ADORA3, which is an example of a significant GR-response eQTL. Expression levels are stratified based
on the eSNP genotypes for ADORA3. Baseline (6 p.m.) measures are displayed in blue and GR-stimulated measures (9 p.m.) in red. Microarrays data are
displayed in (C) and their qPCR validation in (D). Q value in (C) is derived from GR-response cis-eQTL analysis and the p value in (D) from the qPCR linear
regression model.(Figure S1A) and combinedwith genome-wide SNPdata. All indi-
viduals showed a strong endocrine response to dexamethasone
(Cortisol: F1,159 = 43.93, p = 5.02 3 10
10 and ACTH: F1,158 =
37.96, p = 5.763 109; Figures S1B and S1C). After quality con-
trol, 4,447 gene expression probes that exhibited strong regula-tion following dexamethasone administration (absolute fold
change in gene expression from baseline to 3 hr post-dexameth-
asoneR 1.3 in at least 20% of all samples) were combined with
genotype data of 2 million imputed SNPs (see Experimental
Procedures). Using the log fold change in gene expressionNeuron 86, 1189–1202, June 3, 2015 ª2015 The Authors 1191
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Figure 3. GR-Response eSNPs Are En-
riched in Enhancer Regions in Multiple
Tissues
Bar graph illustrating the enrichment of GR-
response eSNPs for enhancers in multiple tissues
from the Roadmap Epigenome Project, including
brain tissue. The x axis shows the fold enrichment
and the y axis all brain enhancers all well as the
mean fold enrichment among all hematopoietic
cells (see Figure S2) and brain enhancers. The fold
enrichment for GR-response eSNPs is illustrated
in red and for the permuted baseline eSNPs in
blue. Only the GR-response eSNP enrichment,
which passes a Bonferroni corrected significance
threshold (corrected for the number of all tested
tissues or cells, n = 62) is illustrated. * p % 0.05,
obtained by binomial enrichment test and Bon-
ferroni correction, error bars ± SD.standardized to baseline values as the outcome and restricting
the analysis to a ± 1 Mb cis-region around each probe, we found
that 3,820 GR-response-modulating cis-eQTLs (GR-response
eQTLs) remained significant after accounting for disease status,
age, and BMI and correction for multiple testing (see Experi-
mental Procedures). These comprised 297 unique array probes
and 3,662 unique SNPs. The 3,662 unique GR-response cis-
expression SNPs (eSNPs) can be summarized in terms of inde-
pendent tag SNPs into 296 uncorrelated GR-response cis-
eSNP bins, i.e., sets of SNPs in linkage disequilibrium (LD; see
Experimental Procedures). We defined the tag eSNP as the
eSNP showing the highest association per bin (lowest Q value).
These 296 GR-response cis-eSNP bins correspond to 320 GR-
response cis-eQTL bins, i.e., cis-eSNP bin-probe combinations,
as one cis-eSNP bin can be associated with the regulation of
more than one transcript and vice versa. These GR-response
cis-eQTL bins are listed in Table S1 and illustrated in Figures
2B–2D. Including dexamethasone serum levels or the blood
cell count as covariate did not change the results, excluding
any confounding effects of individual differences in dexametha-
sone concentration and cellular composition (see Supplemental
Information).
To assess the robustness of these GR-response eQTLs, we
validated them in an independent sample of n = 58 (see Experi-
mental Procedures) by performing a sample size-weighted
Z score meta-analysis across both samples. In this analysis,
72% of the GR-response eQTLs could be validated, i.e., showed
a meta-analysis p value equal to or more significant than in
the discovery sample alone (see Experimental Procedures).
This method accounts for the small size of the validation
sample and suggests the robustness ofmost of theGR-response
eQTLs.
Characterization of GR-Response eSNPs
To better understand the properties of these GR-response
eQTLs, we first mapped the GR-eSNPs (n = 3,662 SNPs) to
GR binding regions as defined by ChIP-seq peaks in lympho-
blastoid cell line (LCL) GM12878 (see Experimental Procedures).
We observed a significant enrichment of GR-response eSNPs in
GR binding sites as compared to random SNPs (fold enrich-
ment = 2.4, permutation-based FDR% 0.001).1192 Neuron 86, 1189–1202, June 3, 2015 ª2015 The AuthorsNext, we mapped the distance of the 320 GR-response eQTL
bins to the genomic location of the probe sequence of the respec-
tive regulated transcript (utilizing the closest SNPwithin a bin) and
compared this to the probe distance for baseline cis-eQTL bins,
i.e., the eSNP-probe combinations that showed a significant as-
sociation of the genotype with transcription levels at baseline
(see Supplemental Information). The GR-response eSNP bin-to-
probe distance (mean = 406 kb, standard deviation [SD] =
303 kb, n = 320 bins) was significantly longer (Wilcoxon
p value= 1.033 1050) thanbaseline eSNPbin-to-probedistance
(mean = 149 kb, SD = 232 kb, n = 1,148 bins; Supplemental
Information). This suggests that GR stimulation is associated
with significantly more long-range transcriptional regulation
than baseline gene expression and that distinct regulatory ele-
ments may be involved in baseline versus GR-stimulated gene
transcription.
To determine the regulatory potential of GR-response eSNPs,
we investigated whether they are enriched within enhancer re-
gions as defined by the Roadmap Epigenome Project (Kundaje
et al., 2015) (see Experimental Procedures). GR-response tag
eSNPs were significantly enriched within enhancers in 62
different tissues, including blood cells, but also non-hematopoi-
etic tissue such as brain (see Figure S2). When testing baseline
tag eSNPs, we only observed an enrichment in enhancers in
54% of these 62 tissues. Whether combined enrichment of
both GR-response tag eSNPs and baseline tag eSNPs was
observed seemed to be tissue specific (see Figure S2). In fact,
GR-response eSNPs were more enriched in brain enhancers
than baseline eSNPs, i.e., only one of the eight brain enhancers
significantly enriched with GR-response eSNPs also displayed a
significant enrichment for baseline eSNPs (see Figure 3). In
contrast, we observed equal enrichment for GR-response as
well as baseline eSNPs in primary hematopoietic tissues (see
Figure S2). These results further support the viewpoint that
GR-response eSNPs affect different transcriptional regulators
than baseline eSNPs and suggest possible cross-tissue effects
of these SNPs.
To evaluate whether the long-range regulation of GR-
response eQTLs may be associated with long-range physical
chromatin interaction, we compared our data with that from a
chromatin interaction analysis with paired-end tag sequencing
(ChIA-PET) generated by ENCODE (ENCODE Project Con-
sortium, 2011) in the leukemia cell line K562. For this, we exam-
ined whether regions containing the GR-response eSNP bin and
the corresponding probe gene overlapwith physically interacting
ChIA-PET tags (see Experimental Procedures). Twenty-five
percent of the GR-response eSNP bin-probe gene combinations
overlapped with chromatin interaction signals. This was signifi-
cantly greater than 1,000 equally sized sets of randomly distrib-
uted GR-response eSNP bin, especially when restricting the
analysis to more long-range eSNP bin-probe gene pairs with
distances > 100 kb (fold enrichment>100kb = 1.57, permutation-
based FDR>100kb = 0.007; see Experimental Procedures). To
validate these long-range chromatin interactions, we used a
chromatin conformation capture (3C) assay to confirm a physical
interaction between the eSNP bin regions of the GR-response
eSNP tag rs1379868 in the NRTN locus and the corresponding
GR-stimulated transcript LONP1 (see Figures 4A and 4B), which
is over 130 kb upstream. This eSNP bin includes a GR binding
site and ChIA-PET tags (see Figure 4C), which interact with the
transcription start site of the LONP1 gene. The 3C assay
confirmed an increased chromatin interaction (p = 3.35 3
1023, c2 = 115.15 at baseline) of the eSNP bin with the TSS of
the LONP1 gene (P4 in Figures 4C and 4D) in five LCLs. The
average interaction frequency of these two sites was higher
following stimulation with the GR-agonist dexamethasone
(4.83 versus 5.65). These results suggest that long-range regula-
tion of GR-response eQTLs could be mediated by direct chro-
matin interaction of enhancer regions with the respective
transcription start sites.
GR-Response eSNPs Are Enriched in Loci Nominally
Associated with MDD and Other Psychiatric
Disorders as well as in Genome-wide Significant
Schizophrenia Loci
Besides their functional characterization, an important question
was to assess whether the genetic variants that alter the imme-
diate transcriptional response to GR activation (GR-response
eSNPs) would also be associatedwith risk for stress-related psy-
chiatric disorder. To assess this, we first tested whether our GR-
response eSNPs were overrepresented among SNPs associ-
ated with MDD in the genome-wide association study (GWAS)
results of the Psychiatric Genomics Consortium (PGC), which in-
cludes approximately 9,000 cases and the same number of con-
trols (Ripke et al., 2013). Among nominally associated loci with
MDD (at meta-analysis p value% 0.05), 282 SNPs also represent
a GR-response eSNP. Permutation analysis (see Experimental
Procedures) predicted an expected mean overlap of 210 SNPs
from 1,000 randomly selected SNP sets (fold enrichment =
1.34, permutation-based FDR < 0.001; Figure 5A). We next
investigated whether GR-response eSNPs were also enriched
over baseline eSNPs, as SNPs associated with transcriptional
changes have been shown to be more enriched in GWASs in
general (Roussos et al., 2014). Again the mean overlap for
1,000 permuted baseline cis-eSNP sets (218 SNPs) was signifi-
cantly lower than the actual overlap of GR-response eSNPs (fold
enrichment = 1.29, permutation-based FDR < 0.001; Figure 5A).
These enrichments remain significant when using only the tag
eSNPs (n = 285) to control for possible confounding due to link-age disequilibrium (LD) structure (fold enrichment = 1.31, permu-
tation-based FDR = 0.082).
The 282 GR-response eSNPs that overlap with MDD-associ-
ated SNPs correspond to 23 unique eSNP bins (reflecting 26
eQTL bins) that regulate 25 unique transcripts (Table S2). We
call these 23 eSNP bins ‘‘MDD-related GR eSNP bins’’ in the
remainder of the manuscript to refer to GR-response eSNPs
that also show a nominal association with MDD.
Validation of Enrichment and Extension to Other
Psychiatric Disorders
Wenext examinedwhether theseMDD-relatedGR eSNPswould
also be associated with MDD in an independent sample. For this
we constructed a genetic risk profile score (GRPS) using the
tagging SNPs of the 23 MDD-related GR eSNP bins for each in-
dividual in an independent validation sample of 1,005 MDD
cases and 478 controls (Table S3; see also Experimental Proce-
dures). We found these GRPSs to be significantly associated
with MDD and that individuals with higher GRPSs were overrep-
resented in the case group (Z = 3.76, p = 0.00017; Figure 5B).
This GRPS explains about 2.6% of the total variance for MDD
in this sample, and the association of these MDD-related GR
eSNP GRPSs was more significant than GRPSs constructed
from 1,000 randomly generated SNP profiles (permutation-
based FDR = 0.008; see Experimental Procedures).
As exposure to stressful life events is a strong risk factor not
only for MDD but also for other psychiatric disorders, including
bipolar disorder (BPD) and schizophrenia (SCZ) (Dohrenwend
and Egri, 1981; Kendler and Karkowski-Shuman, 1997), we
tested whether the GR-response eSNPs were also overrepre-
sented among SNPs associated with other psychiatric disorders
utilizing meta-analysis data from the PGC. Using this approach,
we tested for for significant GR-response eSNP enrichment
compared to 1,000 randomly generated baseline eSNP sets
in the PGC for four additional psychiatric disorders and the
cross-disorders analysis including also MDD (see Table 1).
In the latest multi-stage SCZ GWAS, which includes up to
36,989 cases and 113,075 controls (Schizophrenia Working
Group of the Psychiatric Genomics Consortium, 2014), we
detected a significant enrichment of GR-response eSNPs
compared to baseline eSNPs with SNPs associated with SCZ
at p % 0.05 (fold enrichment 1.29, permutation-based FDR %
0.001). When we limited the enrichment analysis to genome-
wide significant SCZ loci, we detected 134 GR-response eSNPs
that overlapped SNPs associated with SCZ at p% 53 108. This
corresponds to a 10-fold enrichment over baseline eSNPs and is
7.75-fold higher than for nominally associated SCZ SNPs (see
Table 1). A significant negative enrichment was identified for
loci associated with attention deficit-hyperactivity disorder (per-
mutation-based FDR% 0.012; ADHD; 840 cases and 1,947 trio
cases) and autism spectrum disorder (ASD; permutation-based
FDR% 0.001; 161 cases and 4,788 trio cases) but not BPD (see
Table 1).
To test whether these enrichments of GR-response eSNPs as
compared to baseline eSNPs are specific to psychiatric disor-
ders, we mapped these variants to GWAS for rheumatoid
arthritis, Crohn’s disease, and height but found no enrichment
more than 1.06-fold (see Table 1). These analyses suggest that
GR-response eSNPs are unrelated to these medical disordersNeuron 86, 1189–1202, June 3, 2015 ª2015 The Authors 1193
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A B Figure 5. GR-Response eSNPs Are En-
richedamongVariantsAssociatedwithMDD
(A) The dotted red line shows the enriched number
of GR-response eSNPs that overlap with SNPs in
our meta-analysis for MDD (= MDD-related GR
eSNPs; 8,864 cases and 8,982 controls). The dis-
tribution of the observed overlap for sets of 1,000
random SNPs (gray) and 1,000 random baseline
eSNPs (blue) are represented as histograms (null
distributions). Both permuted data sets never
reached the same overlap with MDD-associated
SNPs as the GR-response eSNPs.
(B) The distribution of the MDD-related GR eSNP
genetic risk profile scores (GRPSs) for an inde-
pendent sample of MDD cases (n = 1,005 cases;
red) and controls (n = 478; gray) are represented as
density plots. Individuals with MDD display higher
GRPSs (p = 0.00017). p value by logistic regression
model.or general quantitative traits but specifically contribute to the risk
for MDD and SCZ.
Functional Relevance of Transcripts Regulated by
MDD-Related GR eSNPs
Gene Network Analysis of MDD-Related GR Genes
Next, we investigated whether the probe genes (n = 24), regu-
lated by the MDD-related GR eSNPs, are part of specific
pathways that may be relevant for the pathophysiology of psy-
chiatric disorders. Using the GeneMANIA tool (Montojo et al.,
2014), we were able to generate a gene network containing
23 of the 24 MDD-related GR genes (see Figure 6A and Exper-
imental Procedures). Within this network, the type of interac-
tions between the MDD-related GR genes that were most
enriched were: co-expression (1.21 times the number expected
when using other GR-stimulated transcript sets), co-localization
(genes are expressed in the same tissue or proteins are found
in the same location; fold enrichment = 1.21), and shared pro-
tein domains (fold enrichment = 3.77). Several genes, e.g.,
FTH1, CCT7, RPS2, IMPDH2, and PELI1, presented more
than ten interactions. Additional co-expression analysis identi-
fied that the MDD-related GR genes are more tightly co-regu-
lated in blood than in 1,000 sets of randomly chosen transcripts
selected from all GR-responsive transcripts (fold enrichment =
1.04, permutation-based FDR = 0.078). These data provide
support that the MDD-related GR genes functionally interact
to perform an orchestrated function, i.e., they are coordinatedFigure 4. Long-Range Chromatin Interaction of GR-Response eQTLs
(A) Long-range chromatin interaction as exemplified by the eSNP region containin
five lymphoblastoid cell lines (LCLs) each, homozygous for the two opposite SN
NRTN locus (rs1379868) affects the differentially regulated gene expression of
Baseline (6 p.m.) measures are displayed in blue and GR-stimulated measures (
(B) SNP effect on GR-dependent gene transcription was validated by qPCR in th
(C) Characterization of the eSNP locus. Top panel, ideogram for chromosome 1
Bottom panel: 3C-primers (green track) were designed at the LONP1 TSS (C1, an
includes a GR binding site in blood cells (pink track). ChIA-PET tags from the leu
between theNRTN eSNP locus and the regulated gene LONP1. The paired ChIA-P
track) and blood cells (yellow track).
(D) Chromatin conformation capture interaction data. A 3C physical interaction bet
in the 3C libraries made from LCLs (p = 3.35 3 1023, c2 = 115.15) with a strong
Q values in (A) are derived from GR-response cis-eQTL analysis, and p values inin their transcriptional response to GR activation or stress.
A limited network analysis through manually curated interac-
tions from the scientific literature (Lechner et al., 2012) revealed
that these genes show associations with MDD, SCZ, BPD,
neurodevelopmental disorders, posttraumatic stress disorder,
and response to antidepressant treatment in independent data-
sets (see Figure S3). In addition, they seem predominantly
involved in pathways associated with ubiquitination and protea-
some degradation and the inflammatory response, systems
that have been implicated in the pathophysiology of MDD
and SCZ, as well as in stress-related changes in synaptic plas-
ticity (Miller et al., 2009; Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014; Tai and Schuman,
2008).
Convergent Functional Genomics: Integrating Human
MDD-Related GR Genes with Relevant Mouse Models
To establish whether the transcripts regulated by acute GR acti-
vation in blood are also regulated in the brain within a similar time
frame, we investigated whether the orthologs of the 24 MDD-
related GR transcripts were differentially regulated in mouse
blood and brain (prefrontal cortex [PFC], hippocampus [HC],
and amygdala [AM]) 4 hr following dexamethasone administra-
tion (10 mg/kg dexamethasone i.p.). In this experiment, 17 of
the 24 genes had a mouse orthologous gene, and 16 were ex-
pressed above microarray detection threshold. One-third of
the genes showed significant changes at FDR % 0.1 and
53.3% at p % 0.05 in one or more of the investigated braing the NRTN locus (chr10: 5,690,000–5,840,000; hg19) was confirmed by 3C in
P alleles, both in the presence and absence of dexamethasone. A SNP in the
LONP1 in human whole blood cells (based on GR-response eQTL analysis).
9 p.m.) in red.
e LCLs used for the 3C assay.
9 (p13.3). A red box isolates the region shown (enlarged) in the bottom panel.
chor) and multiple regions (P1–P6) in and around the eSNP bin. The eSNP bin
kemia cell line (brown and green tracks) validate a direct chromatin interaction
ET tags coincide with DNaseI hypersensitivity sites in the leukemia cell line (red
ween the LONP1 TSS and eSNP bin (P4), emphasized by a gray box, was found
er interaction following stimulation with the GR-agonist (p = 0.06, c2 = 3.35).
(B) and (D) are derived from linear mixed model; error bars ± SD.
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Table 1. Proportion of GR-Response eSNPs Overlapping with GWAS SNPs with Nominal Significance
GR-Response
eSNPs Random SNPs Fold
enrichment
Baseline eSNPs Fold
enrichmentCount Mean counta Range FDR Mean counta Range FDR
CDA 115 86.5 ± 8.99 SD 61–119 0.001 1.33 102.03 ± 8.57 SD 71–130 0.066 1.13
BPD 91 70.36 ± 8.34 SD 44–100 0.009 1.29 86.18 ± 8.2 SD 59–115 0.295 1.05
SCZ 157 84.08 ± 8.79 SD 61–111 <0.001 1.87 129.07 ± 9.61 SD 99–158 0.027 1.22
SCZ2 948 533.29 ± 21.59 SD 469–615 <0.001 1.78 736.55 ± 22.32 SD 676–813 < 0.001 1.29
SCZ2 (5 3 108)b 134 6.43 ± 2.52 SD 0–18 <0.001 20.94 13.37 ± 3.32 SD 4–24 < 0.001 10.02
ADHD 29 55.69 ± 7.14 SD 36-79 <0.001c 1.89 42.23 ± 5.78 SD 25–63 0.012c 1.44
ASD 34 63.73 ± 7.62 SD 44–91 <0.001c 1.85 114.94 9.09 SD 80–147 < 0.001c 3.35
MDD 282 210 ± 13.9 SD 168–255 <0.001 1.34 218.11 ± 13.49 SD 174–268 < 0.001 1.29
CD 149 83.16 ± 8.89 SD 61–112 <0.001 1.8 150.5 ± 10.27 SD 121–182 0.591 1.006
RA 396 71.9 ± 8.06 SD 46–100 <0.001 5.56 372.37 ± 16.08 SD 323–430 0.078 1.06
Height 350 146.01 ± 11.9 SD 108–188 <0.001 2.4 340.84 ± 14.91 SD 294–390 0.268 1.03
Schizophrenia, SCZ; bipolar disorder, BPD; attention deficit-hyperactivity disorder, ADHD; Crohn’s disease, CD; autism spectrum disorder, ASD;
major depressive disorder, MDD; cross-disorder associations, CDA; rheumatoid arthritis, RA.
aProportion of the number of GR-response eSNPs observed for 1,000 permuted random SNPs and baseline eSNPs.
bOverlap at genome-wide significance level.
cNegative enrichment and inverse fold enrichment.regions. Over 86% of the genes were significantly regulated
(FDR% 0.1) in mouse blood (see Figure 6B left panel).
In order to extend these results from pharmacologic GR ago-
nism, we further evaluated whether acute social defeat stress,
which is commonly used to induce depressive-like behavior,
differentially regulates these same 24 MDD-related genes in
mice. In this experiment, 17 orthologous genes were analyzed
in blood, PFC, AM, and HC samples 4 hr after exposure to an
aggressive resident mouse with short attack latency (Wagner
et al., 2013). Here, three (MKNK2, SLCO3A1, and OCIAD2) of
the five genes that were significantly differently regulated after
dexamethasone stimulation were also significantly regulated
following social defeat (FDR % 0.1) in in one or more of the
analyzed brain regions (see Figure 6B right panel). This suggests
that a subset of MDD-related GR genes is also regulated by
acute social defeat, providing an important extension to
stress-related risk for depression.
Cumulative Risk Scores for the MDD-Related GR eSNPs
Correlate with Dysfunctional Amygdala Reactivity
To investigate the relationship between MDD-related GR eSNPs
and variability in stress-related brain function in humans, we
applied an imaging genetics strategy to data from 647 partici-
pants (171 individuals with current or past DSM-IV Axis I disor-
ders and 476 controls; 306 of participants were self-reported
European-Americans [EUR-AM]; Table S5 and see also Experi-
mental Procedures) of the Duke Neurogenetics Study (DNS)
(see Experimental Procedures). Our analyses focused on centro-
medial amygdala reactivity to canonical threat-related angry and
fearful facial expressions (Figure 7A), because this phenotype is
clearly implicated in the etiology and pathophysiology of stress-
related disorders, including depression (Phillips et al., 2003).
Moreover, amygdala reactivity can trigger rapid physiological
and behavioral responses to threat, including activation of the1196 Neuron 86, 1189–1202, June 3, 2015 ª2015 The Authorsstress hormone response via projections from the medial divi-
sion of the central nucleus of the amygdala, (captured in our
analysis by our centromedial amygdala region of interest) to
the paraventricular nucleus of the hypothalamus (Ulrich-Lai
and Herman, 2009). Lastly, amygdala function is influenced by
the slow-acting, presumably genomic effects of hydrocortisone
administration (Henckens et al., 2010), further highlighting its
importance as a systems-level phenotype sensitive to our
observed GR-induced transcriptional responses.
Higher MDD-related GR tag eSNP GRPSs (Table S4; see also
Experimental Procedures) were associated with blunted centro-
medial amygdala response to angry and fearful facial expres-
sions relative to neutral expressions in the EUR-AM subsample,
even after accounting for age, sex, and the presence of an Axis I
disorder (F1,301 = 7.06, p = 0.008; Figure 7B). This effect was also
observed in the entire sample after accounting for population
stratification (F1,637 = 6.05, p = 0.014; Figure S4A). Permutation
analyses that formed random SNP profiles (n = 1,000; matched
for MAF and not exceeding the maximum correlation among
profile SNPs; see Experimental Procedures) indicated that the
actual GRPS were more likely to be associated with these
differences in amygdala reactivity than 1,000 sets of random
SNP profiles (EUR-AM subsample: permutation-based FDR =
0.003; entire sample: permutation-based FDR = 0.012). Post
hoc analyses revealed that this differential effect was driven
by higher centromedial amygdala reactivity to neutral facial
expressions relative to our control condition in participants
with higher GRPS (EUR-AM subsample: F1,301 = 6.47, p =
0.011; Figure 7D; entire sample: F1,637 = 8.52, p = 0.004; Figures
S4A and S4C). There were no effects of GRPS on amygdala
reactivity to angry and fearful facial expressions relative to our
control condition (EUR-AM subsample: F1,301 = 0.2, p = 0.65;
Figure 7C and entire sample: F1,637 = 0.09, p = 0.76; Figures
S4A and S4B).
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Figure 6. Functional Annotation of Transcripts Regulated by MDD-Related GR Risk Variants
(A) Gene network produced using GeneMANIA. The network consists of 43 genes (circles) connected by 164 interactions (edges). Genes that are within a black
filled circle indicate our MDD-related GR transcripts (n = 24), while those within a gray filled circle indicate additional genes (n = 20). The interactions found
between these genes, which were more enriched than expected, are shown (co-expression: purple lines, shared protein domains: yellow lines, and co-locali-
zation: blue lines).
(B) Heatmap of gene expression changes (log2) between stress versus vehicle groups of mouse in brain and blood (n = 17 mice, left panel) as well as between
baseline and GR-stimulation in human blood cells (blue, middle panel) and in mouse brain and blood (n = 22 mice, right panel). Investigated tissues are labeled
within the bottom row of the heatmap (prefrontal cortex [PFC], hippocampus [HC], and amygdala [AM]). p valueswere computed by using linear regressionmodel,
and significance is indicated by a black box (FDR% 0.1, dotted box p% 0.05).This pattern of altered amygdala reactivity in individuals with
higher GRPS is suggestive of impaired threat-related cue
learning with inappropriately increased reactivity to neutral ex-
pressions, which do not convey threat (Britton et al., 2011; Oli-
veira et al., 2013). Thus, higher GRPS may be associated with
non-specific or overgeneralized threat and stress responses,
which are consistently observed in depression as well as other
mood and anxiety disorders (Britton et al., 2011; Oliveira et al.,
2013).
DISCUSSION
We have shown that common variants in long-range enhancer
elements alter the transcriptional responsiveness of GR target
genes to the GR and that these variants cumulatively increase
the risk for psychiatric disorders, includingMDD and SCZ. These
findings suggest that the risk of developing MDD after adverse
life events may be influenced by an individual’s sensitivity to
the downstream, transcriptional effects of cortisol released dur-
ing the stressful adverse events. In addition, the findings suggest
that the changes seen in the initial transcriptional response to
stressmay influence how an individual processes stressful expo-
sures. Indeed, the risk variants were also associated with over-
generalized centromedial amygdala reactivity to non-threat
stimuli. This is consistent with dysfunctional behavioral andphysiological hyper-responsiveness to threat in MDD and other
psychiatric disorders.
One of our notable genetic findings is that the distance be-
tween the GR-response eSNPs and the regulated gene expres-
sion probe was significantly longer than the distances previously
reported for baseline eQTLs (149 kb baseline eQTLs versus 406
kb for GR-response eQTLs in our dataset). Our data support and
extend previous observations that indicated a long-range tran-
scriptional regulation by the GR (Hakim et al., 2011; John et al.,
2011; So et al., 2007). In fact, a combined analysis of our GR-
response eQTLs and ChIA-PET data from the ENCODE project
(ENCODEProject Consortium, 2011) aswell as a validation using
3C analysis suggests that there could be a physical long-range
interaction between the eSNP locus and the promoter of the
GR-regulated transcript for at least 25% of the GR-response
eQTLs. Additional experiments are necessary in order to investi-
gate the direct effects of the different alleles on the enhancer
function and chromatin conformation in other tissues, including
the brain, to further validate this.
More broadly, our results indicate that stimulated eQTL ap-
proaches using disease-risk-relevant transcriptional stimuli (in
our case GR activation and stress) can identify novel risk genes
for common disorders that may otherwise go undetected. Previ-
ous studies have used eQTLs or DNAmethylation QTLs (mQTLs)
for the annotation of GWAS results and indicated the importanceNeuron 86, 1189–1202, June 3, 2015 ª2015 The Authors 1197
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Figure 7. GR-Response MDD-Related eSNP
GRPS Correlate with Overgeneralized Amyg-
dala Reactivity
(A) Statistical parametric map illustrating left cen-
tromedial amygdala reactivity to facial expressions
with an ‘‘Angry & Fearful > Neutral’’ contrast in the
entire sample (15 contiguous voxels; max voxel MNI
coordinate, x = 24, y = 10, z = 14, t = 4.35, p =
7.76 3 106).
(B) HigherMDD-related GR eSNP genetic risk profile
scores (GRPSs) in the European-American sub-
sample of the DNS cohort (n = 306) predicted
amygdala reactivity to threat-related facial expres-
sions in comparison to neutral facial expressions.
(C and D) Post hoc analyses revealed that GRPSs
did not predict amygdala reactivity to threat-related
expressions (C), but that higher GRPSs predicted
elevated amygdala reactivity to neutral facial ex-
pressions (D) in comparison to non-face control
stimuli. The 95% confidence interval is displayed as
gray shaded band in (B)–(D).of using eQTLs and mQTLs from disease-relevant tissues (Ga-
mazon et al., 2013; Nicolae et al., 2010). While we do not observe
a significant enrichment of baseline blood eQTLs, GR-response
eQTLs from this tissue were significantly enriched, even over
baseline SNPs, among the variants associated with MDD and
SCZ (see Table 1). Interestingly, GR-response eSNPs identified
in whole blood were enriched in enhancers specific to brain tis-
sue, while this was not the case for baseline eSNPs identified in
blood (see Figures 3 and S2). This suggests that GR-response
eSNPs may have more relevance for cross-tissue effects, espe-
cially in the brain. This pattern may underlie the observation that
GR-response eSNPs were associated with psychiatric disorders
and amygdala function, but not with other medical disorders or
height. Our findings support the notion that not only the tissue
but also the type of stimulation, e.g., mimicking aspects of stress
in our experiments, can be relevant for using such QTL studies in
annotating GWAS results.
While these common genetic variants were discovered in pe-
ripheral blood cells, we provide evidence for their importance in
neural circuits that are critical for generating and regulating the
stress axis response to adversity. First, GR-response eSNP re-
gions are enriched in enhancers relevant in brain tissue. Second,
a number of the transcripts affected by these MDD-related GR
eSNPs in their GR-regulated gene expression in human blood
were also regulated by short-term GR activation or following
exposure to acute social defeat stress in the mouse hippocam-
pus, prefrontal cortex, or amygdala. Third, using imaging ge-
netics, we demonstrate that the cumulative MDD-related GR
tag eSNP genetic risk profile predicts overgeneralized reactivity
of the human amygdala. It has to be noted, however, that while1198 Neuron 86, 1189–1202, June 3, 2015 ª2015 The Authorsthe GR-response eQTLs were identified
using the selective GR agonist dexametha-
sone, the GR shares response elements
with other steroid receptors, especially
the mineralocorticoid receptor, so that we
cannot exclude an important contribution
of these other receptors.Furthermore, the MDD-related GR genes formed a strongly in-
terconnected gene network (over 85% of the genes are co-ex-
pressed; Figure 6A). Within this network, inflammation was the
pathway with the highest connectivity (see Figure S3), and a
number of studies indicate the pathophysiological relevance of
this system in the development of MDD and SCZ (Haroon
et al., 2012; Keller et al., 2013; Miller et al., 2009). The role of
the immune system was also supported by results of the latest
GWAS meta-analysis for SCZ (Schizophrenia Working Group
of the Psychiatric GenomicsConsortium, 2014). The connectivity
of this system was followed in strength by the connectivity of
proteasome degradation. It has been shown, for example, that
activation of GRs enhances ubiquitin/proteasome-mediated
degradation of glutamate receptor subunits and thereby medi-
ates cognitive impairment induced by repeated stress exposure
(Yuen et al., 2012). Genetic modulation of GR effects on the im-
mune system in addition to ubiquitin/proteasome-mediated
degradation thus provide a mechanistic link between risk for
psychiatric disorders and the genetic differences in GR-induced
gene expression.
Most importantly, our GR-response eQTL analysis revealed an
enrichment of these GR-response eSNPs among MDD-associ-
ated SNPs over baseline eSNP sets as well as random SNP
sets. This suggests that SNPs altering the initial transcriptional
response to stress also influence the risk for MDD. The associa-
tion was verified in an independent cohort. Furthermore, the
increased risk conferred by these functional variants may extend
to SCZ. This is consistent with evidence from recent studies of
psychiatric disorders, which suggest shared genetic risk loci,
with MDD having the highest co-heritability with BPD followed
by SCZ (Lee et al., 2013). The fact that we do not detect a signif-
icant enrichment of GR-response eSNPs with BPD, despite the
large SNP co-heritability of this disorder with both SCZ and
MDD, may in part be due to the smaller sample size in this
meta-analysis and thus insufficient power to detect true associ-
ations (n = 6,704 cases for BPD versus over 9,000 cases for MDD
and SCZ1). The fact that the fold enrichment of GR-response
eSNPs with SCZ increases with sample size (SCZ1: n = 9,087
cases versus SCZ2: n = 36,989 cases) and p value cut-off
(p < 0.05 and p < 5 3 108) suggests that the strategy of using
stimulated eQTL approaches may help in identifying true associ-
ations for disease. Interestingly, we find that four MDD-related
GR eQTL bins, which are not only associated with MDD but
also with SCZ, and the cross-disorder associations from the
PGC analyses (Table 1) reach genome-wide significance for
SCZ in the most recent meta-analysis (Schizophrenia Working
Group of the Psychiatric Genomics Consortium, 2014). Besides
the extended MHC region (chr6: 26–34 Mb, hg19), these
overlapping risk loci include a region on chr1: 149,998,890–
150,242,490 (hg19) that now ranks 48th for association with
SCZ and overlaps with the MDD-related GR eQTL bin, ANP32/
PLEKHO1, that regulates the probe gene HIST2H2AA3/4. This
GR-response eQTL drives the overlap with genome-wide
SCZ2 associations, and it has been validated using qPCR (Sup-
plemental Information). These findings suggest that GR-
response eSNPsmay contribute to the shared risk between psy-
chiatric disorders, especially MDD and SCZ, and that this
approach may delineate between shared and specific risk fac-
tors for these disorders.
Results from our imaging genetics study provide one potential
neural pathway by which MDD-related GR eSNPs may increase
the risk for the development of stress-related psychopathology,
including depression. Interestingly, MDD-related GR eSNPs pre-
dict heightened amygdala reactivity to stimuli that do not inher-
ently signal threat (i.e., neutral facial expressions). This suggests
that MDD-related GR eSNPs associated with the immediate
transcriptome response to stress may impair the neural circuitry
that supports the learning of threat-related cues and, possibly,
thereby contribute to the overgeneralization of threat-related
stress responses. Indeed, in healthy individuals, the genomic
effects of hydrocortisone result in more specific reactivity to
threatening stimuli (Henckens et al., 2010). As such, MDD-
related GR eSNPs may underpin a less adaptive and overgener-
alized amygdala response that leaves individuals more likely to
perceive threat in the absence of unambiguous cues; this in
turn may lead to the development of cognitive biases associated
with depression, or perhaps even paranoia, in the context of
schizophrenia.
The data presented in this study show that common genetic
variants that change the GR-mediated immediate transcriptome
response to stress are linked, in the long-term, to both changes
in neural processing of threat and increased risk for MDD and
SCZ. Our data lend further support to the notion of a possible
shared genetic liability of some psychiatric disorders and specif-
ically point to stress-responsive genes as common risk factors.
Studies dissecting how these genetic variants alter the molecu-
lar, cellular, and neural response to glucocorticoids in the short
and long term could inform the development of novel strategiesfor the prevention and treatment of stress-related psychiatric
disorders.
EXPERIMENTAL PROCEDURES
Samples and Study Designs
MPIP Cohort
The subject pool for the eQTL analysis consisted of 164 male Caucasian indi-
viduals: 93 healthy probands and 71 in-patients with depressive disorders
treated at the Max Planck Institute of Psychiatry’s hospital in Munich,
Germany (MPIP cohort; see Supplemental Experimental Procedures;
Hennings et al., 2009; Menke et al., 2012 for details). Baseline whole-blood
samples (for plasma and RNA) were obtained at 6 p.m. after 2 hr of fasting
and abstention from coffee and physical activity. Immediately afterward the
participants were given 1.5 mg dexamethasone orally. A second blood draw
was performed 3 hr later at 9 p.m. (see Figure 2A). Cortisol and ACTH serum
levels were determined using previously described radioimmunoassays (Hen-
nings et al., 2009; Menke et al., 2012). Plasma dexamethasone concentrations
were assessed in serum samples drawn at 9 p.m. using liquid chromatog-
raphy-tandem mass spectrometry on API4000 (AB Sciex).
MARS Cohort
This sample included 1,483 participants with European ancestry (1,005 with
MDD) recruited for the MARS project at the MPIP in Munich. All individuals
used within the eQTL study (MPIP cohort) were not part of this sample (see
Supplemental Experimental Procedures and Hennings et al., 2009 for details).
DNS Cohort
The imaging genetics analysis was conducted on data from (1) a European-
American subsample of 306 participants (63 with DSM-IV Axis I disorder)
and (2) a full sample of 647 participants (117 with DSM-IV Axis I disorder) of
the ongoing Duke Neurogenetics Study (see Supplemental Experimental Pro-
cedures). All participants completed awidely utilized functionalmagnetic reso-
nance imaging (fMRI) paradigm assessing threat-related amygdala reactivity
(see Supplemental Experimental Procedures).
Mouse Models
Twenty-two male C57BL/6N mice were used for the dexamethasone-stimula-
tion test (DEX-mouse). The experiment was performed twice with two separate
batches of mice (n = 22 per batch). Animals were injected i.p. with either
vehicle (VEH, n = 11) or 10 mg/kg dexamethasone (DEX, n = 11) between
9 a.m. and 11 a.m. Animals were sacrificed 4 hr post-injection.
The acute social defeat sample included 17 male C57BL/6N mice (n = 8
control and n = 9 acute stress mice) taken from a larger study that were
used for this experiment. Mice underwent the acute social defeat stress
once exactly 4 hr preceding sacrifice and tissue collection. The acute social
defeat paradigm was performed as described previously (Wagner et al.,
2013) on a single day between 9 a.m. and 12 p.m. (see Supplemental Exper-
imental Procedures).
From both animal models described above, blood was collected and the
brain was carefully extracted and dissected (see Supplemental Experimental
Procedures). The following brain regions were collected: hippocampus (HC),
prefrontal cortex (PFC), and the amygdala (AM).
All human studies have been approved by the respective local ethics com-
mittees and all individuals gave written informed consent. Details about the
individual studies are listed below or in the Supplemental Experimental Proce-
dures. The mouse model protocols were approved by the Committee for the
Care and Use of Laboratory Animals of the Government of Upper Bavaria,
Germany.
Gene Expression Data
The human whole-blood RNA of the MPIP cohort samples was hybridized to
Illumina HumanHT-12 v3.0 array. All array probes have been subjected to an
extensive quality control (QC; see Supplemental Experimental Procedures).
For the GR-response eQTL analysis, only transcripts that showed a differ-
ence in gene expression between the samplings at 6 p.m. and 9 p.m. with
an absolute fold change R 1.3 in at least 20% of all samples were catego-
rized as robustly effected by dexamethasone stimulation (n = 4,630 tran-
scripts) and further used in the analysis. The position of the array probesNeuron 86, 1189–1202, June 3, 2015 ª2015 The Authors 1199
and possible SNPs within these sequences were annotated using ReMOAT
version August 2009 (Barbosa-Morais et al., 2010), leaving 4,447 autosomal
array probes for the GR-response eQTL analysis (see Supplemental Experi-
mental Procedures).
DEX-mouseRNAsampleswerehybridizedon IlluminaMouseRef-8v2.0chips,
and the mouse RNA from the acute social defeat mouse model was hybridized
on Illumina MouseWG-8 v2.0 chips. QC was applied separately for each tissue
and experiment as described in Supplemental Experimental Procedures.
Genotype Data
Human DNA from MPIP and MARS cohort subjects was extracted from EDTA
blood samples and genotyped on Illumina Human610-Quad/Human660W-
Quad arrays (MPIP cohort) and Illumina Sentix Human-1/HumanHap300/
Human610-Quad/HumanOmniExpress arrays (MARS cohort). From the SNP
data surviving QC, imputation of additional variants was performed using
IMPUTE v2 (Howie et al., 2009; see Supplemental Experimental Procedures
for more detail on genotyping QC and imputation).
The MARS GRPSs included alleles from 20 of the 23 tag eSNPs (three SNPs
diverged from HWE in the MARS sample, see Table S3). See also Supple-
mental Experimental Procedures.
Human DNA from participants of the DNS cohort was isolated from saliva
and genotyped on the Illumina HumanOmniExpress array as well as a custom
array containing an additional 300,000 SNPs. The DNS GRPSs included
alleles from 19 of the 23 tag eSNPs (four SNPs not present on genotyping
array; see Table S4 and Supplemental Experimental Procedures).
Statistical Analysis
The eQTL analysis (MPIP cohort) was restricted to those SNP-probe pairs that
map within a region of 1 Mb upstream or downstream of the gene expression
probe, in order to detect cis-eQTLs. To measure the transcriptional response,
we used the log fold change in gene expression changes between 6 p.m.
(baseline) and 9 p.m. (GR-stimulation) standardized to baseline.
PLINK v1.07 (Purcell et al., 2007) was used to test for cis-association be-
tween all imputed SNPs and transcriptional response. As eQTL data were
composed of two kinds of data, genotyping and expression data, we used
two stages of multiple testing correction: (1) SNP level correction: for each
cis-region (array probe), we performed a permutation test. The sample identi-
fiers in the gene expression data were shuffled in order to preserve the struc-
ture in the genotype data (LD). A total of 500,000 permutations were carried out
per probe, and the empirical p values were adjusted using the Westfall-Young
correction for the number of SNPs per probe, i.e., maxT procedure of Westfall-
Young (Westfall and Young, 1993). (2) Probe level correction: cis-regions with
an extensive LD structure will increase the number of false positive eQTLs
(Westra et al., 2013). Therefore, we applied the Benjamini-Hochberg method
to correct the maxT-adjusted p value significance by using only the most sig-
nificant and independent SNPs per probe (tag SNPs). The number of tag
eSNPs per cis-region was identified by LD pruning and ‘‘clumping’’ the
SNPs using the ‘‘clump’’ command in PLINK (using distance < 1 Mb and
r2 % 0.2 as setting). Each tag SNP forms a SNP bin by aggregating SNPs at
r2 % 0.2 and distance < 1 Mb. SNPs within a given bin were correlated to
the tag SNP, but not to any other tag SNP of an other SNP bin. We limited
the false-positive SNP-probe pairs to less than 5% and therefore considered
the FDR analog of the p value (Q value) < 5% as statistically significant.
Validation of GR-response cis-eQTL results was carried out with a sample
size-weighted Z score meta-analysis (Evangelou and Ioannidis, 2013) in an
additional independent dataset using peripheral blood samples of 58 individ-
uals (see Supplemental Experimental Procedures). A GR-response cis-eQTL
was validated if the meta-analysis p value was less than the actual maxT-
adjusted p value in the discovery sample alone.
The genomic control inflation factor (lgc; Devlin and Roeder, 1999) was
calculated for every GR-response eQTL gene expression probe (n = 297)
based on the genome-wide genotype data (lgc). The inflation factor was
computed in PLINK as median c2 statistic. The median lgc over all probes
is 1, which implies no large inflation was present.
We used NR3C1 ChIP-seq data obtained from the ENCODE Project
(ENCODE Project Consortium, 2011) to determine actual GR binding at GR-
response eSNPs (see Supplemental Experimental Procedures).1200 Neuron 86, 1189–1202, June 3, 2015 ª2015 The AuthorsTo determine whether GR-response eSNPs were enriched for functional re-
gions, we annotated them using HaploReg (Ward and Kellis, 2012) and
compared the results to a realistic null distribution based on permuted baseline
eSNP sets (see Supplemental Experimental Procedures).
ChIA-PET data were obtained from the UCSC Genome Browser (http://
hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeGisChiaPet;
see Supplemental Experimental Procedures).
To identify whether GR-response eSNPs were enriched for association
with MDD, SCZ, BPD, ADHD, ASD, Crohn’s disease, rheumatoid arthritis,
and the GWAS loci for height, we integrated our data with results from the
previously published GWAS analysis (see Supplemental Experimental Proce-
dures). To prove the significance of the MDD-related GR SNPs for MDD, we
used a logistic regression model to test the association of the MDD-related
GR tag eSNP GRPSs for disease status in the independent MARS cohort.
Gender, BMI, and age were used as covariates. To establish the null distri-
bution, we generated 1,000 random SNP profiles by swapping individual
labels to provide new SNP profiles under the null hypothesis. To further
account for the genomic LD structure, we limited the analyses to tag SNPs
(tag SNP = SNP showing the highest association per cis-eQTL bin) and
generated 1,000 randomized SNP sets; conditional on MAF and each of
the same size as the GR-response tag SNPs overlap with MDD associations
(n = 285).
The gene network analysis was performed using the online tool
GeneMANIA (Montojo et al., 2014). To establish the null-distribution, we
calculated the gene network for ten sets of randomly chosen GR-response
transcripts (n = 4,422). Finally, we determined the average gene network
results in order to establish the relationship between MDD-relevant
GR-response transcripts and non-MDD-relevant but GR-response tran-
scripts. Network categories showing a fold enrichment > 1 are reported in
Figure 6A.
For the co-expression analysis, we used the GR-response residuals from all
array probes (n = 4,422) to determine if the 25 MDD-related GR array probes
are more co-regulated than 1,000 sets of randomly chosen GR-stimulated
transcripts (see Supplemental Experimental Procedures).
A disease-related network was built bymanual curation and literaturemining
using the CIDeR database (Lechner et al., 2012) and the yED software (yWorks
GmbH, Tu¨bingen).
To test the relationship of the GR-response eSNPs and threat-related amyg-
dala reactivity, we used an imaging genetics strategy as described in the Sup-
plemental Experimental Procedures.
Chromatin Conformation Capture Analysis
3C was carried out in five LCLs as described in Hage`ge et al., 2007 and
detailed in the Supplemental Experimental Procedures.
qPCR Validation
Quantitative real-time PCR (qPCR) was used to validate the association be-
tween eSNPs and GR-stimulated gene expression of ADORA3 (the probe
with the most significant GR-response eQTL) and HIST2H2AA3/HIST2H2AA4
(the probe with the most eSNPs overlapping with data from our meta-analysis
for MDD) in whole blood cells and for a long-range GR-response eQTL-NRTN
in five LCLs, which were also used with the 3C assay. More details are pro-
vided in Supplemental Experimental Procedures.
ACCESSION NUMBERS
Data from the human gene expression microarray experiment were deposited
at the GEO repository under GEO: GSE46743.
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